AdjuTec Pharma AS, a privately held company specializing in antibiotic resistance breakers, has entered into a research collaboration agreement with Venus Remedies Limited (India). As part of this agreement, Venus Remedies will conduct a preclinical evaluation of AdjuTec Pharma’s APC-148 platform technology.
Restoring Antibiotic Effectiveness
AdjuTec Pharma has developed novel inhibitor technologies that selectively eliminate antibiotic resistance mechanisms in multidrug-resistant bacteria, thereby restoring the effectiveness of commercially available antibiotics. APC-148, the company’s lead program, is currently undergoing phase 1 clinical trials. Venus Remedies is a leader in antimicrobial resistance (AMR) research. The company will use its advanced R&D capabilities to evaluate APC-148’s potential. This study aims to enhance antibiotic efficacy against multidrug-resistant bacterial strains.
Preclinical Study to Assess APC-148
Venus Remedies will test APC-148 in combination with various antibiotics against its extensive library of clinical isolates collected through the GASAR study. This initiative aligns with Venus Remedies’ broader commitment to combating AMR and contributing to the United Nations’ ‘One Health’ objective.
Addressing a Growing Global Health Crisis
Both AdjuTec Pharma and Venus Remedies are committed to tackling the global health crisis posed by AMR. Currently, AMR causes 1.3 million deaths worldwide each year. If left unchecked, it could result in an estimated 39 million cumulative deaths by 2050. Without effective intervention, AMR may surpass cancer as the leading cause of mortality.
The Urgency of AMR in India
India faces a particularly severe AMR crisis, with over 300,000 deaths attributed to AMR in 2019 alone, including among newborns. APC-148 offers a promising solution to restore the potency of antibiotics against resistant bacterial strains. It is placing an increasing burden on India’s healthcare system.
Statements from Industry Leaders
As per the press release, Jethro Holter, CEO of AdjuTec Pharma AS, expressed enthusiasm about the collaboration, stating: “We are delighted to partner with Venus Remedies, a leading Indian pharmaceutical company that shares our commitment to developing more effective antibiotics to combat the escalating AMR crisis. This agreement aligns with our strategy to collaborate with international pharmaceutical leaders. Together, we aim to address the most clinically challenging resistant pathogens using our groundbreaking technology.”
Mr. Saransh Chaudhary, President of Global Critical Care at Venus Remedies and CEO of Venus Medicine Research Centre, also emphasized the significance of the partnership: “We are pleased to collaborate with AdjuTec Pharma on the preclinical evaluation of APC-148. This research engagement allows us to leverage our expertise in AMR to advance scientific understanding and novel solutions in this field. Our collaboration highlights a shared commitment to addressing the global AMR challenge through rigorous, innovation-driven research.”